Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;17(15):1629-1636.
doi: 10.2217/pgs-2016-0077. Epub 2016 Sep 20.

Patient experiences with pharmacogenetic testing in a primary care setting

Susanne B Haga  1 , Rachel Mills  1 , Jivan Moaddeb  1 , Nancy Allen Lapointe  2 , Alex Cho  1 , Geoffrey S Ginsburg  1
Affiliations

Patient experiences with pharmacogenetic testing in a primary care setting

Susanne B Haga et al. Pharmacogenomics. 2016 Oct.

Abstract

Aim: To investigate patient experiences with pharmacogenetic (PGx) testing.

Methods: Patients were offered PGx testing through a study on pharmacist-assisted delivery of PGx testing and invited to complete pre- and post-testing surveys about their experience.

Results: Of 63 patients tested, 17 completed the baseline survey (27%). Interest in testing was mostly impacted by desire to inform selection of best treatment (n = 13). Seven of 12 patients that completed the follow-up survey indicated that their provider discussed the test result with them. Five patients understood their test result very or somewhat well. All would be likely to have PGx testing again.

Conclusion: Patients perceived PGx testing to be useful, though more effort may be needed to improve patient-provider communication of test results.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was supported by NIH grant RO1GM081416. SBH is a consultant to Inova Translational Medicine Institute (Falls Church, VA, USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 2006;6(1):16–21. - PubMed
    1. Miguel A, Azevedo LF, Araujo M, et al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 2012;21(11):1139–1154. - PubMed
    1. Burton MM, Hope C, Murray MD, et al. The cost of adverse drug events in ambulatory care. AMIA Annu. Symp. Proc. 2007;11:90–93. - PubMed
    1. Hug BL, Keohane C, Seger DL, et al. The costs of adverse drug events in community hospitals. Jt Comm. J. Qual. Patient Saf. 2012;38(3):120–126. - PubMed
    1. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief. 2010;(42):1–8. - PubMed

Publication types

LinkOut - more resources